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Abstract 
BACKGROUND: Prostate hyperplasia and prostate cancer are two of the most common pathological condition of 
the prostate to be found on male. Both of these diseases share common pathogenesis involving inflammation of 
prostatic tissues. Chronic inflammation will induce the release of cytokines, followed by cells injury and tissues 
damage. One of the cytokines that play a role in prostate pathology is IL-6. The inflammation will also induce the 
releases of anti-inflammatory cytokines such as TGFβ-1. 
AIM: This study aims to analyse the expression of IL-6 and TGFβ-1, in prostate hyperplasia and prostate cancer.  
MATERIAL AND METHODS: This is an observational study, using paraffin-embedded tissue samples of prostate 
hyperplasia and prostate cancer. Samples were obtained from the laboratory of Pathological Anatomy, Faculty of 
Medicine, Andalas University, Padang, Indonesia. Immunohistochemistry was performed to detect the cytokine 
expression, and a semiqunatitaves measurement according to Immunoreactive score (IRS) was performed for 
evaluation. For the TGFβ-1, the stromal expression was also analysed by measurement of the stromal stained 
area. The correlation of cytokine expression to Gleason index score was also analysed in prostate cancer.  
RESULTS: The result showed that this study found that TGFβ-1 was detected both in the stromal component as 
well as epithelial. With the stromal being the dominant site of expression. The stromal TGFβ-1 expression was of 
significantly higher in prostate hyperplasia compares to prostate cancer (p < 0.05), while the epithelial expression 
of TGFβ-1 was not found to be significantly different. IL-6 was mostly expressed intracytoplasmic in epithelia. The 
IL-6 expression was significantly higher in prostate cancer compared to hyperplasia. However, there was no 
significant correlation to found between IL-6 expression to the Gleason Score among prostate cancers.  
CONCLUSION: This study concluded that there were differences in expression of both TGFβ-1 and IL-6 between 
prostate hyperplasia and prostate cancer tissue by immunohistochemistry. 
 
 
 
Introduction 
 
The benign prostate hyperplasia and prostate 
cancer are the most common pathological condition to 
be found on the male's urothelial system. An 
epidemiological study showed that the incidence of 
this disease was increasing annually, worldwide [1]. 
Prostate hyperplasia is the most common benign 
neoplasm on elderly male. Histopathological study on 
autopsy reports showed that the prevalence of 
prostate hyperplasia was found up to 50% on males 
between 50-60 years of age, and it increases to over 
80% in the 70 years group of ages [1], [2], [3], [4], [5]. 
In the other hand, prostate cancer is the most 
common non-skin cancer to be found on male, 
worldwide. This disease serves as the second most 
killer cancer among males in the United States and 
Europe [2], [6].  
Prostate hyperplasia and prostate cancer 
share a similar pathogenesis, in which both are 
related to hormones and inflammation [7], [8], [9]. 
Despite having different predilection, both diseases 
are known as a chronic disease that has an early 
initiation, followed by a slow progression course, until 
it shows clinical symptom [2], [7]. In the recent five 
years, it has been revealed that chronic inflammation 
of prostate tissue is one of the risk factors for both 
prostate hyperplasia and prostate cancer [2], [3], [7], 
[10], [11], [12]. Although the pathogenesis is still 
unclear, nowadays there are many studies showed 
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the relations of chronic inflammation to both prostate 
hyperplasia and prostate cancer [3], [4], [9], [13]. 
Recently the treatment of BPH and prostate cancer 
also started to incorporate the prevention and 
treatment of chronic inflammation as an integrated 
treatment [10], [14], [15], [16].  
Chronic inflammation will induce the release 
of cytokine and other inflammatory factors, both from 
inflammatory cells, as well as the hypoxic prostate 
epithelium [1], [17]. These cytokines will interact with 
stromal cells and cause further tissue damage [2], 
[17]. The inflammation will induce infiltrations of T 
cells, B cells and macrophages [8], [18]. These 
inflammatory cells will induce the release of the 
proinflammatory IL-2, IL-8 and IL-6 from epithelial as 
well as stromal cells [19]. In return, the increasing of 
proinflammatory cytokines will induce the production 
and secretion of an anti-inflammatory cytokine such 
as TGF β and FGF. The complex interaction of those 
cytokines will eventually affect the function of prostate 
gland [18], [19], [20], [21], [22]. TGF-β is known as a 
controlling factor of tumour progressiveness. This 
cytokine has a biphasic role in carcinogenesis. On the 
early phase of cancer, it serves as a tumour 
suppressor agent by inhibiting cell proliferation [23], 
[24]. However, on the later stage, it functions as a 
tumour promoter, in which, it will induce the cellular 
changes related to tumour cells invasion [23], [24], 
[25].  
IL-6 is a cytokine that involves in the 
malignancies process and could serve as a factor that 
inhibits the apoptosis of tumour cells as well as 
inducing angiogenesis [24], [26], [27], [28]. Pace et al. 
(2011) showed that the IL-6 was found to be 
significantly higher on a patient with prostate cancer 
compared to prostate hyperplasia [27]. The present 
study aims to analyse the differential expression of 
cytokines that involves in the pathogenesis of BPH 
and prostate cancer, especially TGFβ-1 and IL-6 in 
prostate tissues.  
 
 
Materials and Methods 
 
Experimental Design 
The present study used formalin fixed paraffin 
embedded tissues from prostate lesion obtained from 
a surgical procedure. Forty samples of previously 
diagnosed as histologically, (29), as well as 40 
samples of prostate cancers, were used in this study. 
The tissues were obtained from the laboratory of 
pathological anatomy, Faculty of Medicine, Andalas 
University, Padang, Indonesia. 
 
Immunohistochemistry  
Immunohistochemistry was used to 
investigate the expression of cytokines using the 
avidin-biotin complex method. Following primary 
antibody were used; Rabbit polyclonal anti-human 
TGFβ-1, Bioss, 0086R with a dilution of 1:200, and 
Rabbit polyclonal anti-human IL-6. Bioss, 07-82R, with 
dilution 1:100. The goat anti-rabbit Igg, Vector 
laboratories, of dilution 1:200 was used as secondary 
antibody and the 3-3’ diaminobenzidine (DAB), 
Dojindo Laboratories, was applied as the chromogen. 
The immunohistochemistry was performed as 
suggested in the primary antibody datasheet 
accordingly. The cellular expression of the cytokines 
was performed by a semi-quantitative system 
according to Immunoreactive score (IRS). Both the 
proportion and intensity of cellular staining were 
measured. The final IRS score is the multiplication of 
proportion score to intensity score, which ranges 
between 0 to 12. In this present study, the IRS score 
of 0 to 4 was considered as “low IRS score”, and the 
score above 4 is treated as “high IRS score”. The 
stromal staining of TGFβ-1were also analysed by 
measuring the proportion of stained area using the 
Image J software, (Image J 1.49v software, National 
Institute of Health, Bethesda, MD, USA). For the 
samples of prostate cancer, the correlation of cytokine 
expression to the Gleason score was also analysed. 
The prostate cancers samples were grouped either as 
“high Gleason score” (score 8-10) or “low Gleason 
score” (score 7 or below).  
 
Statistical analysis 
Chi-square was used for statistical analysis. 
And the Shapiro-Wilk test was performed as a test of 
normality. 
 
 
Results 
 
Before data analysis, the distribution of data 
was assessed for normality test. Since each of the 
groups contains less than 50 samples, the normality 
test was performed with the Shapiro-Wilk test, as 
shown in Table 1.  
Table 1: Normality Test for Independent Variables  
Variables Group 
Shapiro-Wilk 
Statistic df Sig. 
TGFβ-1 Prostate hyperplasia 0.852 40 0.000 
Prostate cancer 0.743 40 0.000 
IL-6 Prostate hyperplasia 0.955 40 0.109 
Prostate cancer 0.914 40 0.005 
 
Table 1 shows the distribution of variables. 
None of the variables shows a normal distribution (p < 
0.05). Therefore, the test was continued by 
transforming the data, and a repeating normality test 
was performed, as shown in Table 2. 
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Table 2: Post-Transformation Normality Test  
Variables (Log) Group Shapiro-Wilk 
Statistic df Sig. 
LOG TGFβ-1 Prostate hyperplasia 0.899 23 0.024 
Prostate cancer 0.946 24 0.223 
LOG IL-6 Prostate hyperplasia 0.799 23 0.000 
Prostate cancer 0.868 24 0.005 
 
Post-transformation normality test showed 
that only TGFβ-1 on prostate cancer data shows 
normal distribution. Therefore, to investigate the 
correlation between independent and dependent 
variables, the statistical analysis will be done using 
the non-parametric Mann Whitney test. The value of 
each variable will be presented by the average value 
and standard of deviation.  
 
The Epithelial Expression of TGFβ-1 on 
 Prostate Lesions 
Immunohistochemistry shows that TGFβ-1 
was expressed both in the epithelial component as 
well as the stromal component (Figure 1). However, 
the majority of the staining with strong signal 
intensities were to be found in the stromal area. The 
epithelial expression of TGFβ-1 can be found in 
prostatic epithelial both in prostate hyperplasia as well 
as prostate cancer (Figure 1A and B). Most of the 
staining of the TGFβ-1 in prostate hyperplasia 
showing of low expression in IRS score (97.5%). 
Prostate cancer also mostly showed low TGFβ-1 
epithelial expression (87.5%) (Table 3). The average 
IRS values of TGFβ-1 epithelial expression is slightly 
lower in prostate Hyperplasia (IRS score 0.7) 
compared to the prostate cancer group (IRS score 
1.3). However, the differences are statistically non-
significant. Interestingly there are 5 samples of 
prostate cancers that showed high epithelial TGFβ-1 
expression as can be seen in Table 3 and Figure 1B.  
 
Figure 1: The Expression of TGFβ-1 by Immunohistochemistry on 
Human Prostate Tissue. Prostate Hyperplasia (A) and Prostate 
Cancer (B). TGFβ-1 are mostly Expressed on Stromal Component 
Prostate Hyperplasia (A); The Stromal Staining is Greatly Reduced 
in Prostate Cancer, However Cancer Epithelial can Show TGFβ-1 
Staining in Some Cases (B) Immunoperoxidase of Rabbit Anti 
Human TGFβ-1. Scale Bar 100 µm 
 
Table 3 shows the expression of epithelial 
TGFβ-1 on prostate hyperplasia and prostate cancer. 
Both groups show mostly low IRS scores. The 
carcinoma groups contain slightly higher IRS score. 
However, there are no significant differences to be 
found between groups (p = 0.21). 
Table 3: The Epithelial Expression of TGFβ-1 on Prostate 
Hyperplasia and Prostate Cancer Tissue  
Group n 
Epithelial TGFβ-1 (IRS Score) 
Low (%) High (%) p 
Prostate hyperplasia  40 39 (97.5%) 1 (2.5%) 0.201 
Prostate carsinoma 40 35 (87.5%) 5 (12.5%) 
 
 
The Stromal Expression of TGFβ-1 on 
 Prostate Lesions  
The immunohistochemistry staining of TGFβ-
1 showed a distinct pattern between hyperplasia and 
prostatic cancer. Most of the prostate hyperplasia 
showed a high stromal staining intensity surrounding 
the gland (Figure 1A and 2A). In the other hand, 
prostate cancer shows low expression of TGFβ-1 in 
the stromal area (Figure 1B and 2C). The 
measurement of stromal staining was done by Image 
J software by selecting the brown staining area, 
converting the image into a black and white image 
and measured the stained area.  
 
Figure 2: The Expression of TGFβ-1 by Immunohistochemistry on 
Human Prostate Tissue. Prostate Hyperplasia (A) and Prostate 
Cancer (B); The Stomal Area is Measured by Image J Software by 
Isolate the Brown Stained Area and Measuring the Proportion of 
Stained Area. There is a Higher Proportion of Stained Area in 
Prostate Hyperplasia (B) Compared to Prostate Cancer (D). 
Immunoperoxidase of Rabbit Anti Human TGFβ-1. Scale Bar 100 
µm 
 
The average stromal area of TGFβ-1 in 
prostate hyperplasia is 15.3% and is significantly 
higher compares to that of the prostate cancer 4.5%. 
The stromal expression of TGFβ-1 can be seen in 
Table 4. 
Table 4: The Stromal Expression of TGF-β1 on Prostate 
Hyperplasia and Prostate Cancer Tissue 
Group n 
TGFβ-1 (% Area) 
Average Value St-Deviation p 
Prostate hyperplasia  40 15.32 8.74 0.00 
Prostate carcinoma 40 4.47 4.84 
 
 
Table 4 shows the expression of stromal 
TGFβ-1 on prostate hyperplasia and prostate cancer. 
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There is a significantly higher expression of TGFβ-1 
on hyperplasia prostate, compared to prostate 
cancers (p < 0.05).  
 
The Expression of IL-6 on Prostate 
 Lesions and its Correlation to the Gleason 
 Score in Prostate Cancer  
Immunohistochemistry shows that IL- 6 was 
expressed in the epithelial component both in 
hyperplasia prostate and prostate cancer. The 
staining can also be detected in the stromal area but a 
faintly low intensity (Figure 3). The majority (62.5%) of 
prostate hyperplasia showed low expression of IL-6 in 
IRS score, in contrast, the majority (85%) of samples 
in carcinoma group showed a stronger expression, as 
can be seen in Table 5.  
 
Figure 3: The Expression of IL-6 by Immunohistochemistry on 
Human Prostate Tissue. Prostate Hyperplasia (A) and Prostate 
Cancer (B). IL-6 is Expressed on Low Intensity on Prostate 
Hyperplasia (A). The Expression is Higher in Prostate Cancer Cells 
(B) Immunoperoxidase of Rabbit Anty Human IL-6. Scale Bar; 
100µm 
 
Table 5 shows the expression of IL-6 on 
prostate hyperplasia and prostate cancer. There is a 
significantly higher expression of IL-6 on prostate 
cancers compared to hyperplasia prostate (p < 0.05).  
Table 5: The Expression of IL-6 on Prostate Hyperplasia and 
Prostate Cancer Tissue  
Group n 
IL-6 (IRS Score) 
Low High p 
Prostate hyperplasia  40 25 (62.5%) 15 (37.5%) 0.001 
Prostate carsinoma 40 6 (15%) 34 (85%) 
 
 
When the prostate cancer was grouped into 
“high” and “low” Gleason score index group, both 
groups showed high IL-6 IRS score, there is no 
significant correlation between IL-6 expression to the 
Gleason index score in prostate cancer, as can be 
seen in Table 6.  
Table 6: The Correlation of Gleason Score to the Expression of 
IL-6 on Prostate Carcinoma 
Gleason Score n 
IL-6 IRS score (%) 
Low High p 
Low 40 1 (7.1%) 13 (92.9%) 0.399 
High 40 5 (19.2%) 21 (80.8%) 
 
Discussion 
 
The Expression of TGFβ-1 on Prostate 
 Lesions: Prostate Hyperplasia and 
 Prostate Cancer  
Chronic inflammation plays a significant role 
in the initiation and progression to the wide spectrum 
of pathogenesis in prostate lesions. The inflammation 
will attract the infiltrations of B cells, T Cells, as well 
as macrophages. These immune cells will increase 
the secretion of proinflammatory cytokine IL-2, IL-6 
and IL-8 both on the epithelial tissue or from storms. 
In response to the increases of proinflammatory 
cytokines, the epithelial and stromal cells will produce 
anti-inflammatory cytokines such as TGFβ-1 and FGF, 
which in turn will affect the normal function of prostate 
glands. 
In this present study, we found that TGFβ-1 
was highly expressed in hyperplasia prostate tissue in 
the extracellular matrix surrounding the glands. The 
expression of TGFβ-1 was significantly different 
compared to prostate cancer. This result is suggesting 
that TGFβ-1 play an important role in prostate 
hyperplasia pathogenesis. It has been known that 
TGFβ-1, acts as a modulator of other protein such as 
bFGF 2, synthesis of extracellular matrix and 
angiogenesis via VEGF. This interaction plays roles in 
the pathogenesis of hyperplasia prostate.  
TGFβ-1 is a potent mitotic factor for fibroblast 
as well as other mesenchymal cells [22], [30]. It also 
regulates the synthesis of the extracellular matrix and 
induces the secretion of fibrogenic bFGF-2. TGFβ-1 
expression act as chemoattractant towards fibroblast, 
which played roles in the early process of fibrosis on 
early phase and was instrumental in the process of 
fibrosis [31]. TGFβ-1 stimulates fibroblast 
transformation into myofibroblast and smooth muscle 
cells through induction of extracellular matrixes. Other 
studies showed the role of TGFβ-1 in fibrosis. 
Zuhirman (2014) shows the increases of TGFβ-1 in 
chronic ureteral obstruction [32]. Untergasser et al., 
(2005) showed the increases of TGFβ-1 stimulates 
the collagen synthesis by stromal cells on prostate 
hyperplasia, as well as the transformation of fibroblast 
into myofibroblast [6]. 
In Contrast to prostatic hyperplasia, our 
present study shows that there are decreases in 
stromal TGFβ-1 expression in prostate cancer. 
Interestingly we also found the increases of 
cytoplasmic expression of TGFβ-1 in some samples. 
There were variations of the stromal TGFβ-1 
expression level among prostate cancer in our study, 
and the average values of stained area proportion 
were of 4%. Most prostate cancers in the present 
study show negative cytoplasmic staining of TGFβ-1, 
19 samples showed positive staining but only on a low 
level (IRS score 1). TGFβ-1 was known to have a 
biphasic role in carcinogenesis and has been well 
known as a factor of tumour progression in the early 
phase TGFβ-1 act as a tumour suppressor by 
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inhibiting cell proliferation, and induces cells 
differentiation as well as apoptosis. However, in the 
late stage, TGFβ-1 loses its tumour suppressing-
function and act as a tumour promoter. In the present 
study, most of our samples showed a low expression 
of TGFβ-1 in cancer cells, suggesting a decreased 
synthesis or secretion of this protein in prostate 
cancer. The low expression might have roles in the 
pathogenesis of prostate cancers. Loss of TGFβ-1 
function with low expression was also reported in 
some cancers such as breast, ovarium, oesophagus, 
and head and neck cancer.  
However, in the late stages of carcinogenesis, 
TGFβ-1 can play an opposite function as a tumour 
growth promoter. It is suggested that some tumour is 
actively secreted TGFβ-1 in the late stages of 
carcinogenesis. The TGFβ-1 in these tumour plays a 
complex role related to angiogenesis, immune cells 
suppression, cellular transformation related to 
invasiveness and metastatic ability, as well as 
mediating interactions of tumour cells and 
extracellular matrix. Interestingly in our present study, 
we found 5 samples with higher expression of TGFβ-1 
(IRS score 4). The high TGFβ-1 expression on some 
cancer cells raises the question of whether these 
differences related to the biological behaviour of 
tumour cells, the tendencies to metastasise or other 
clinical outcomes. Further study is required to 
answers these questions in prostate cancers. 
 
The Expression of IL-6 on Prostate 
 Lesions; Prostate Hyperplasia and 
 Prostate Cancer 
Chronic inflammation plays a significant role 
in the initiation and progression of the prostate lesion. 
Inflammation was believed to have a strong 
correlation to prostatitis, prostatic hyperplasia and 
prostate cancer. Inflammation will invite T cells, B 
cells and macrophages to the prostate glandular 
structures and stroma. After the initiation process, the 
dendritic cells will be activated and maintained the T 
cells responses within the prostate gland; this will 
cause a chronic and progressive pathological process 
that will eventually facilitate the progression of 
prostate hyperplasia or prostate cancer. 
Immune cells infiltration will increase the 
secretion of a pro-inflammatory cytokine such as IL-2, 
IL-6, and IL-8. The activation of various cytokines will 
disrupt the balance of cell proliferation a d apoptosis. 
IL-6 is produced by various type of cells, including 
macrophages endothelial, and lymphocytes. IL-6 
expression and can be detected both intracellular 
within cells cytoplasm as well on extracellular matrix. 
Higher expression of IL-6 was detected on a prostate 
cancer group with strong intensities. In the other hand, 
most of the prostate hyperplasia showed weak 
expression of IL-6.  
Our present study showed a similar result with 
some other study. Engelhard et al. (2014) found that 
the expression of IL-6 in prostate cancer is 
significantly higher compared to prostate hyperplasia 
[20]. We also observed a variation of IL-6 expression 
among prostate cancer; 7 of the samples exhibit a 
high IL-6 expression of IRS score 9 or above. The 
strong expression in some of prostate cancer samples 
raises the question of whether this finding has any 
relation to the biological behaviour of cancer cells. 
Duscharla et al. (2017) reported that a high serum 
level of IL-6 is related to the bone metastasis of 
prostate cancer [33]. 
IL-6 secreted by immune cells infiltrate will be 
captured by IL-6-R, this will activate JAK, STAT3 and 
MAPK pathway, these, in turn, will induce cell 
proliferation through androgen receptor 
inductionangiogenesis and facilitates metastasis. IL-6 
are also known to induce intraprostatic testosterone 
through activation of steroidogenic enzymes. 
Iliopoulos et al. (2009) suggested the correlation 
between inflammation, IL-6 activation, STAT1, PI3K, 
and NFkB in the pathogenesis of prostate cancer. 
Another study also confirmed that the increase of IL-6 
was correlated to the prognosis and showed a 
negative relation to the survival rate. Based on the 
above results, the present study supports the theory 
that IL-6 plays a role significant role in the 
pathogenesis and progression of prostate cancer (34). 
However, in the present study, the expression 
of IL-6 was not correlated to the Gleason score 
significantly. Our study employed 
immunohistochemistry to detect the expression of IL-6 
in prostate tissues. The nature of IL-6 as a soluble 
cytokine could sometimes be difficult to be measured 
quantitatively by immunohistochemistry. Further study 
is required to investigate the relation of IL-6 to the 
Gleason score quantitatively, using a different and 
more sensitives method.  
In summary, the present study reveals the 
differential expression of TGFβ-1 and IL-6 between 
prostate hyperplasia and prostate cancer. The TGFβ-
1 were highly expressed in the stromal component of 
prostate hyperplasia, compared to prostate cancer. In 
the other hand, the IL-6 showed a higher expression 
in prostate cancer cells compared to prostate 
hyperplasia. Further study is required to investigate 
the function of each cytokine in the pathogenesis of 
prostate lesion.  
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